Publications by authors named "Jean-Marc Vidal"

Claim this Profile
A
A call for action on the development and implementation of new methodologies for safety assessment of chemical-based products in the EU - A short communication.
Derek J Knight, Hubert Deluyker, Qasim Chaudhry, Jean-Marc Vidal, Alie de Boer

Regul Toxicol Pharmacol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical review on the Environmental Risk Assessment of medicinal products for human use in the centralised procedure.
Laura Caneva, Milton Bonelli, Marisa Papaluca-Amati, Jean-Marc Vidal

Regul Toxicol Pharmacol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
Falk Ehmann, Kumiko Sakai-Kato, Ruth Duncan, Dolores Hernán Pérez de la Ossa, Ruben Pita, Jean-Marc Vidal

Nanomedicine (Lond)· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Report of the EPAA-ECVAM workshop on the validation of Integrated Testing Strategies (ITS).
Agnieszka Kinsner-Ovaskainen, Gavin Maxwell, Joachim Kreysa, João Barroso, Els Adriaens, Jean-Marc Vidal

Altern Lab Anim· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A generic operational strategy to qualify translational safety biomarkers.
Katja Matheis, David Laurie, Christiane Andriamandroso, Nadir Arber, Lina Badimon, Jean-Marc Vidal

Drug Discov Today· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Juvenile animal studies for the development of paediatric medicines: a description and conclusions from a European Medicines Agency workshop on juvenile animal testing for nonclinical assessors.
Beatriz Silva-Lima, Mette Due Theilade-Thomsen, Jacqueline Carleer, Jean-Marc Vidal, Paolo Tomasi

Birth Defects Res B Dev Reprod Toxicol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop.
Jean-Marc Vidal, Thomas T Kawabata, Robin Thorpe, Beatriz Silva-Lima, Karin Cederbrant

Cytokine· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards consensus practices to qualify safety biomarkers for use in early drug development.
Frank D Sistare, Frank Dieterle, Sean Troth, Daniel J Holder, David Gerhold, Jean-Marc Vidal

Nat Biotechnol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium.
Frank Dieterle, Frank Sistare, Federico Goodsaid, Marisa Papaluca, Josef S Ozer, Jean-Marc Vidal

Nat Biotechnol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimisation of the post-validation process: the report and recommendations of ECVAM Workshop 67.
Annamaria A Bottini, Natalie Alepee, Barry Phillips, Laura Gribaldo, Odile De Silva, Jean-Marc Vidal

Altern Lab Anim· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using a survey of industry practices.
James L Weaver, Naohisa Tsutsui, Shigeru Hisada, Jean-Marc Vidal, Steven Spanhaak

J Immunotoxicol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis